(Q38203821)

31 August 2017

title

A review of CT-P13: an infliximab biosimilar (English)

1 reference

31 August 2017

1

Kate McKeage

1 reference

31 August 2017

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

28

1 reference

31 August 2017

issue

3

1 reference

31 August 2017

page(s)

313-321

1 reference

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Inequities in access to biologic and synthetic DMARDs across 46 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

The role of biosimilars in the treatment of rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-014-0094-1

10.1007/S40259-014-0094-1

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference